Clinical Trial

Effect of Aerobic Exercise on Clinical Symptoms During the Ovarian Cycle

Study acronym: OVARIANEXERCYC
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 3, 2025 (before its estimated May 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the effects of moderate-to-high intensity aerobic exercise on primary dysmenorrhea, a common condition characterized by painful menstrual cramps. The study will involve women diagnosed with primary dysmenorrhea, who will be randomly assigned to one of two groups: Experimental Group: Participants will perform a supervised aerobic exercise program tailored to their fitness level. Control Group: Participants will continue their usual care without any additional interventions. The study will run from February 2025 to April 2025 in Madrid, Spain. Before starting, all participants will complete a questionnaire to gather information about their demographics, menstrual cycle characteristics, medical history, and physical activity levels. This will help ensure an accurate diagnosis of primary dysmenorrhea and provide baseline data for comparison. Participants will be randomly assigned to their groups using a computer-generated sequence, with allocation managed confidentially to avoid bias. The study's single-blind design ensures that the evaluators will not know the group assignments. The goal of this research is to determine whether regular aerobic exercise can serve as an effective, non-pharmacological intervention to reduce the severity of menstrual pain and improve the quality of life for women with primary dysmenorrhea. The findings will inform patients, families, and healthcare providers about potential lifestyle strategies to manage this condition.
Trial Details
NCT Number NCT06804473
Lead Sponsor Universidad Francisco de Vitoria
Conditions Primary Dysmenorrhea
Enrollment 44 participants
Start Date 2025-03-01
Primary Completion 2025-05-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-03